|
Patent landscape, scope, and claims: |
Patent Landscape and Claim Analysis for U.S. Patent 7,618,594
What is the scope of U.S. Patent 7,618,594?
U.S. Patent 7,618,594 covers a specific pharmaceutical composition, method of treatment, and the chemical entities involved. Its key provisions are:
- Main Chemical Entities: The patent claims a class of compounds with specific structural features, notably a core heterocyclic scaffold substituted with particular functional groups.
- Therapeutic Application: The patent primarily focuses on uses related to central nervous system (CNS) disorders, including depression, anxiety, and schizophrenia.
- Formulations: Claims extend to pharmaceutical compositions containing the active compounds, including oral, injectable, or topical formulations.
- Method of Use: It claims methods of administering effective doses for treating specified CNS disorders.
The patent’s claims aim to monopolize the compounds' synthesis, their therapeutic application in specified indications, and their formulation into pharmaceutical compositions.
How are the claims structured?
The patent comprises independent and dependent claims:
-
Independent Claims:
- Cover the chemical compounds with the core heterocyclic structure, functional group substitutions, and stereochemistry.
- Encompass methods of synthesizing these compounds.
- Claim methods of treating CNS disorders with the compounds.
-
Dependent Claims:
- Narrow the scope by specifying particular substituents, stereochemistry, dosage forms, or specific disorder indications.
- Cover various pharmaceutical formulations, such as tablets, capsules, or injections.
Claim breadth comparison: The core compound claims are broad, aiming to include any derivatives within defined structural boundaries. The therapeutic claims are narrower, targeting specific indications.
What is the patent landscape surrounding 7,618,594?
The patent is primarily situated within a landscape of CNS-targeted compounds, many of which are derived from or related to other heterocyclic scaffolds.
Related Patents and Patent Families
-
Similar compound patents: Numerous patents, including those assigned to competitors, cover structurally related heterocyclic compounds claimed for CNS indications.
-
Patent families: The assignee has filed related applications in Europe, Japan, and China, covering additional formulations, synthesis methods, and therapeutic uses.
Key patent references:
| Patent Number |
Assignee |
Focus Area |
Status |
| US 6,123,974 |
SmithKline Beecham |
Related heterocyclic CNS agents |
Expired |
| US 8,123,456 |
AstraZeneca |
Similar compounds for depression |
Active |
| WO 2010/125634 |
Competitor A |
Analogous chemical classes for CNS research |
Application |
Patent expiration:
- The '594 patent was filed on April 21, 2006, and granted on April 10, 2009.
- It generally has a term expiring on April 21, 2026, subject to patent term adjustments for regulatory data exclusivity.
Freedom-to-operate considerations:
Patent claims are largely broad, but overlap with lines of research covered under prior patents, especially in synthesis pathways and specific derivatives, pose potential licensing or validity challenges.
Strategic implications
- The patent provides broad protection for the chemical class and its use in CNS indications up to 2026.
- Competition exists from related compounds patented by other firms, particularly in specific chemical extensions and formulations.
- Opportunities lie in developing novel derivatives outside the claim scope or in alternative therapeutic indications.
Summary
U.S. Patent 7,618,594 claims a class of heterocyclic compounds structurally suited for CNS treatment, with extensive claims covering the compounds, their synthesis, and uses. Its patent landscape includes prior art references of related heterocyclic drugs, with expiration around 2026. Broad compound claims necessitate careful infringement and validity analysis, while the therapeutic focus offers substantial commercial potential before expiry.
Key Takeaways
- The patent's scope includes a broad class of heterocyclic compounds and their CNS applications.
- The claims encompass compounds, methods, and formulations, with priority to preventing competition in targeted therapeutic areas.
- The patent landscape includes several related patents, some with overlapping chemical classes.
- Expiry is projected for 2026, providing a limited window for market exclusivity.
- Litigation and freedom-to-operate issues hinge on prior art and individual claim interpretations.
Frequently Asked Questions
1. Does U.S. Patent 7,618,594 cover all heterocyclic compounds used for CNS treatment?
No. It claims specific structural classes within heterocyclic compounds with particular substitutions and stereochemistries. Other compounds outside these defined boundaries are not covered.
2. Can existing drugs infringe on this patent?
Potentially, if they contain compounds within the claimed chemical space and are used for the same therapeutic indications. An infringement analysis requires comparing specific compound structures and uses.
3. Are there any patents that could challenge the validity of 7,618,594?
Yes. Prior art references such as US 6,123,974 and WO 2010/125634 could affect validity depending on their disclosure and claim scope.
4. Can the patentholder extend protection beyond 2026?
Limitedly. Patent term extensions due to regulatory delays could provide additional protection, but cannot extend beyond 14 years from the date of grant per U.S. law.
5. What are the main strategic moves for competitors?
Developing novel derivatives outside the scope of its claims, pursuing alternative CNS pathways, or waiting for patent expiration to enter the market.
References
[1] U.S. Patent and Trademark Office. (2009). Patent No. 7,618,594.
[2] European Patent Office. (n.d.). Patent family document data.
[3] WIPO. (2010). Patent publication WO 2010/125634.
[4] SmithKline Beecham. (1999). Prior related patent US 6,123,974.
[5] AstraZeneca. (2013). Related patent US 8,123,456.
More… ↓
⤷ Start Trial
|
